Biomarkers of Multisystem Treatment Burden in Adults With Complex Chronic Conditions

Abstract

The recognition and quantification of treatment burden in adults with complex chronic conditions have emerged as critical aspects of modern patient-centered care. Biomarkers, both molecular and clinical, offer the potential to objectively assess and monitor the multisystem impact of therapeutic regimens. This review synthesizes current evidence on the epidemiology, pathophysiology, risk factors, clinical features, diagnostic strategies, and management approaches to treatment burden, with an emphasis on biomarker-driven insights, recent advances, and guideline recommendations. The aim is to enhance clinical decision-making and optimize outcomes for this vulnerable patient population.

Introduction

Adults living with complex chronic conditions often face a substantial treatment burden, defined as the workload of healthcare and its impact on patient functioning and well-being. Multisystem involvement, polypharmacy, frequent healthcare interactions, and the need for self-management create a cumulative strain that can compromise adherence, quality of life, and clinical outcomes. Traditional clinical assessments inadequately capture this multidimensional phenomenon, underscoring the need for objective, validated biomarkers. This review explores the current landscape of biomarkers for multisystem treatment burden, integrating mechanistic underpinnings, clinical implications, and evolving research directions, with a focus on practical utility for healthcare professionals.

Epidemiology / Disease Burden

The prevalence of complex chronic conditions such as diabetes, heart failure, chronic kidney disease, and chronic obstructive pulmonary disease continues to rise globally, with over 25% of adults in developed nations affected by multimorbidity. Treatment burden, distinct from disease burden, refers to the cumulative impact of healthcare-related activities, which may include medication management, monitoring, lifestyle modifications, and frequent consultations. Epidemiological studies reveal that up to 40% of patients with multiple chronic illnesses experience high treatment burden, leading to increased healthcare utilization, reduced adherence, and poorer health outcomes. The multisystemic nature of these conditions complicates both assessment and intervention, necessitating new paradigms for burden quantification.

Pathophysiology

Treatment burden manifests through interconnected physiological, psychological, and social mechanisms. Polypharmacy, a hallmark of complex chronic care, can result in drug-drug and drug-disease interactions, cumulative organ toxicity, and altered pharmacodynamics. Molecular biomarkers, such as elevated inflammatory cytokines (e.g., IL-6, TNF-α), oxidative stress markers, and dysregulated neuroendocrine mediators, have been associated with increased allostatic load. Chronic activation of stress pathways particularly the hypothalamic-pituitary-adrenal (HPA) axis exacerbates multisystem dysfunction, accelerating frailty and functional decline. The interplay between biological stress responses and treatment workload underscores the importance of integrated biomarker profiling.

Risk Factors

Key risk factors for elevated treatment burden include advanced age, low health literacy, socioeconomic disadvantage, cognitive impairment, and the presence of multiple comorbidities. Psychosocial factors, such as inadequate social support and high psychological distress, further modulate the experience and physiological sequelae of treatment workload. Recent studies suggest that genetic predispositions, such as polymorphisms affecting drug metabolism or stress response, may influence biomarker profiles and vulnerability to treatment burden. Recognizing these risk factors is essential for targeted screening and intervention.

Clinical Features

Clinically, treatment burden presents as decreased medication adherence, missed appointments, neglect of self-care tasks, and worsening health-related quality of life. Patients may report fatigue, cognitive overload, emotional distress, and physical symptoms attributable to polypharmacy or treatment side effects. Objective clinical features can include fluctuations in vital signs, laboratory evidence of end-organ dysfunction, and increased frailty indices. Biomarkers such as elevated C-reactive protein, NT-proBNP (in heart failure), and markers of renal injury (e.g., NGAL, cystatin C) may reflect cumulative physiological stress, guiding clinical suspicion of excessive treatment burden.

Diagnosis

Diagnosis of multisystem treatment burden remains challenging due to its subjective and multifactorial nature. Structured assessment tools, such as the Multimorbidity Treatment Burden Questionnaire (MTBQ) and the Patient Experience with Treatment and Self-management (PETS) scale, provide standardized patient-reported outcomes. However, the integration of biomarkers into diagnostic algorithms is an emerging frontier. Composite biomarker panels including measures of inflammation, neuroendocrine activation, and organ-specific stress are being investigated for their ability to objectively quantify treatment burden and predict adverse outcomes. Measurement of allostatic load, for example, utilizes a combination of blood pressure, waist-hip ratio, serum cortisol, inflammatory cytokines, and metabolic markers.

Treatment & Management

Effective management of treatment burden requires a multidisciplinary, patient-centered approach. Strategies include medication reconciliation and deprescribing to minimize polypharmacy, streamlining care processes, and enhancing patient education. Utilization of digital health tools can facilitate monitoring and reduce logistical barriers. Biomarker-guided management such as using NT-proBNP to titrate heart failure therapy or monitoring renal biomarkers for nephrotoxic drug avoidance enables personalized treatment adjustments. Regular assessment of treatment burden, both subjectively and via biomarkers, supports dynamic care planning and early intervention.

Recent Advances / Emerging Therapies

Recent advances focus on the development and validation of novel biomarkers to capture multisystem stress more comprehensively. Metabolomics and proteomics platforms are uncovering unique molecular signatures associated with high treatment burden. Circulating microRNAs and extracellular vesicles are being explored as minimally invasive biomarkers reflecting cumulative organ stress and systemic inflammation. Artificial intelligence and machine learning models are increasingly used to integrate multidimensional biomarker data, facilitating risk stratification and individualized care pathways. Furthermore, interventions targeting reduction of allostatic load such as structured exercise, stress reduction programs, and pharmacological modulation of neuroinflammation are under active investigation.

Guideline Recommendations

Contemporary clinical guidelines emphasize routine assessment of treatment burden as part of comprehensive chronic disease management. The European Society of Cardiology and American College of Physicians recommend considering both patient-reported and objective measures when tailoring therapy in multimorbid populations. The integration of biomarker data is encouraged for risk assessment, therapy optimization, and monitoring of potential adverse effects. Guidelines advocate for shared decision-making, explicit deprescribing protocols, and regular review of treatment plans to balance efficacy with patient capacity and preferences.

Conclusion

The implementation of biomarker-driven approaches to assess and manage multisystem treatment burden marks a significant advance in the care of adults with complex chronic conditions. By combining molecular insights with clinical acumen and patient-centered strategies, clinicians can better identify those at highest risk, personalize therapeutic regimens, and mitigate the adverse impact of treatment workload. Ongoing research into novel biomarkers and integrative care models promises to further refine these strategies, supporting optimal outcomes in this vulnerable and growing patient population.